AAVantgarde Strengthens Leadership With Appointment Of Rasmus Holm-Jorgensen As Chief Financial Officer

AAVantgarde Bio, an international clinical-stage biotechnology company specializing in gene therapy, has announced the appointment of Mr. Rasmus Holm-Jorgesen as its new Chief Financial Officer (CFO). The company is focused on developing treatments for rare diseases using its two proprietary Adeno-Associated Viral (AAV) vector platforms designed for large gene delivery. In his new role, Mr. Holm-Jorgesen will be part of the company’s executive leadership team and will report directly to Dr. Natalia Misciattelli, Chief Executive Officer of AAVantgarde.

Mr. Holm-Jorgesen brings over 25 years of extensive experience in strategy development, financial management, and global operations within the biopharmaceutical industry. Most recently, he served as CFO at Acrivon Therapeutics, Inc. Prior to that, he was a founding team member at Kiniksa Pharmaceuticals, where he held the position of Chief Strategy and Portfolio Officer from 2015 to 2022. During his tenure, he played a key role in driving the company’s initial public offering (IPO) and the successful launch of its first commercial product.

Dr. Natalia Misciattelli, Chief Executive Officer of AAVantgarde, said in a statement, “We are thrilled to welcome Rasmus Holm-Jorgensen as our new CFO. His deep experience in strategy, finance, and global operations—combined with a proven track record of leading innovative biopharmaceutical companies through transformational growth—makes him uniquely suited to guide our next chapter. Rasmus brings not only strategic insight but a strong sense of purpose that aligns with our mission to deliver life-changing therapies to patients.”

“I am honoured to join AAVantgarde at such a pivotal time in its growth. The company’s commitment to innovation and its focus on improving patient outcomes deeply resonate with me. I look forward to working with the leadership team to build on the strong foundation already in place and to help realise the company’s strategic and financial objectives”, added Mr. Rasmus Holm-Jorgensen, Chief Financial Officer of AAVantgarde.

Earlier in his career, Mr. Holm-Jorgesen was Group Vice President and General Manager at Synageva BioPharma between 2011 and 2015. There, he led the establishment of a new rare disease business unit, significantly contributing to Synageva’s $9 billion acquisition by Alexion Pharmaceuticals. He began his professional journey at Novo Nordisk, where he held various international leadership roles, gaining valuable operational experience across global markets.

Mr. Holm-Jorgesen holds a Master of Science degree in Economics from the University of Copenhagen. He has also completed executive education programs at prestigious institutions including INSEAD, Stanford University, and Harvard Business School. With his deep industry knowledge and proven leadership in high-growth biopharma companies, Mr. Holm-Jorgesen is expected to play a crucial role in supporting AAVantgarde’s strategic growth and financial planning as the company advances its gene therapy programs toward clinical and commercial success.